Pharmacovigilance

For the longest time, companies stayed away from trying out new tech stacks in pharmacovigilance (PV). But with the rise of generative AI, things are changing-fast. Big players like Bayer teamed up with Genpact to use AI for automating case intake. Sanofi joined hands with IQVIA to apply AI for end-to-end case processing. And these are just a couple of examples. As case volumes keep going up year after year, everyone’s now in a race to bring AI into the game-to cut costs, boost quality, speed up case processing, and let safety teams focus on what really matters....

A few months ago, I had an insightful conversation with a PV leader who asked about the current opportunities within PV technology for a CRO. Like most, my initial response was a generic suggestion—embrace AI, automate processes, and so on. However, this post isn’t about the usual recommendations you hear everywhere. Now that I’ve spent considerable time in the pharmacovigilance domain, I’ve encountered specific bottlenecks that persist in PV technology companies....